ALNY Stock Overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$147.41 |
52 Week High | US$218.88 |
52 Week Low | US$143.52 |
Beta | 0.39 |
1 Month Change | 0.28% |
3 Month Change | -21.38% |
1 Year Change | -21.39% |
3 Year Change | 2.26% |
5 Year Change | 75.13% |
Change since IPO | 2,352.75% |
Recent News & Updates
Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Recent updates
Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy
Aug 29Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity
Aug 18APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win
Aug 04Alnylam to target abdominal obesity after research data on gene mutation
Jul 27Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out
Jul 19Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jun 21Shareholder Returns
ALNY | US Biotechs | US Market | |
---|---|---|---|
7D | -1.1% | -2.1% | -0.1% |
1Y | -21.4% | 10.4% | 28.4% |
Return vs Industry: ALNY underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: ALNY underperformed the US Market which returned 28.4% over the past year.
Price Volatility
ALNY volatility | |
---|---|
ALNY Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALNY's share price has been volatile over the past 3 months.
Volatility Over Time: ALNY's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 2,100 | Yvonne Greenstreet | https://www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
ALNY fundamental statistics | |
---|---|
Market cap | US$18.57b |
Earnings (TTM) | -US$440.24m |
Revenue (TTM) | US$1.83b |
10.2x
P/S Ratio-42.2x
P/E RatioIs ALNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALNY income statement (TTM) | |
---|---|
Revenue | US$1.83b |
Cost of Revenue | US$310.41m |
Gross Profit | US$1.52b |
Other Expenses | US$1.96b |
Earnings | -US$440.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.50 |
Gross Margin | 83.02% |
Net Profit Margin | -24.08% |
Debt/Equity Ratio | -1,086.8% |
How did ALNY perform over the long term?
See historical performance and comparison